Journal Club: Efficacy & Safety of Subcutaneous Guselkumab: 48-Week Results from the Phase 3 GRAVITI Study
Thank you to Johnson & Johnson for your support of this Journal Club Video Module.The GRAVITI study provides compelling Phase 3 data on guselkumab, an IL-23 p19 subunit inhibitor, demonstrating its ef...
18 Maalis 20254min
GHAPPcast: The Clinical Utility of Guselkumab in UC
Thank you to Johnson & Johnson for your support of this GHAPPcast episode.Join us for a compelling episode of GHAPPcast, the official podcast for advanced practice providers in gastroenterology and he...
11 Maalis 202526min
KOL: What Are the Most Critical Updates in Cirrhosis Research That Clinicians Should Be Aware Of?
Cirrhosis is often considered an irreversible liver disease, but is there a chance for early-stage reversal? In this episode, Janet Gripshover, CRNP, Nurse Manager for the Cedars-Sinai Liver Transplan...
6 Maalis 20254min
KOL: How Can Healthcare Professionals Improve Patient Outcomes in Those with Cirrhosis?
Cirrhosis is a progressive liver disease that requires early detection, effective management, and patient education to improve outcomes. In this video, Allison Moser, NP, a Transplant Hepatology Nurse...
4 Maalis 20253min
Journal Club: Efficacy and Safety of Guselkumab in Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results
Explore the latest findings on Guselkumab as a maintenance therapy for moderate to severe ulcerative colitis from the Phase 3 QUASAR Maintenance Study. In this Journal Club video module, Shayla Schoen...
27 Helmi 20255min
FAQ: How does the guselkumab data align with the STRIDE II guidelines?
Thank you to Johnson & Johnson for your support of this FAQ Video Module.In this video, Erin Darguzas, NP, from the Inflammatory Bowel Disease Center at Northwestern Medicine, discusses how Guselkumab...
25 Helmi 20252min
Medication Review: What are guselkumab's other FDA indications and how might that affect patient care?
Thank you to Johnson & Johnson for your support of this Medication Review Video Module.In this video, Anne Feldman, NP, from Cleveland Clinic, discusses Guselkumab (Tremfya), an FDA-approved treatment...
20 Helmi 20252min
KOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis?
In this video, Sherona Bau, NP, at Pfleger Institute at UCLA, shares the latest advancements in cirrhosis management, including newly FDA-approved medications and updated AASLD (American Association f...
19 Helmi 20252min
